An interventional study of Heartfelt device in Heart Failure, sponsored by Heartfelt Technologies. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.
Sponsored by Heartfelt Technologies · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 482 studies in Heart Failure with a site in United Kingdom — 100 open to participants now, 127 under way, 18 of them phase 3. Heart Failure · United Kingdom.
Among the 482 studies in Heart Failure with a site in United Kingdom, this one is the 251st largest by enrollment of the 314 interventional ones that give a count, is one of 25 that started in 2021, is one of 146 with no phase, and was the 323rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →100 of the 482 studies in Heart Failure with a site in United Kingdom are open now. Recruiting first, the newest first:
Coventry University · Sites in United Kingdom
Ages 18–90
Oslo University Hospital · Sites in United Kingdom, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 29 more countries
Ages 18+
Axon Therapies, Inc. · Sites in United Kingdom, Czechia, Georgia and 2 more countries
Ages 40+
Bayer · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages up to 18
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
482 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 64 · Phase 3 78 · Phase 4 17
First in 1983; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 120 across the 314 interventional studies, 281 across the 166 observational. Of the 291 that completed or were terminated, 105 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
218 of 482 have an industry lead sponsor. The 10 most frequent:
Heartfelt Technologies is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Heartfelt Technologies has 8 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
30 of the studies in Heart Failure with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT06271577AliveCorSmartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II | 2026-12 |
Add all 30 to your calendar (.ics) → With an account.
Among the 482 studies in Heart Failure with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with heart failure (HF) who recently received treatment with IV diuretics for worsening congestion or outpatients with HF and peripheral oedema treated with at least 80 mg furosemide (or equivalent)/day will be recruited for the LOVE-HF trial at Blackpool Victoria Hospital.
Eligible participants will be randomized to use the Heartfelt Device alongside standard care (weighing + symptom reporting), or standard care alone. Participants and clinicians will be blinded (double blind) as to which arm participants are in, and after 30 days, participants will be crossed over to the other arm. This can be done without disrupting patients as the Heartfelt device can be switched remotely from a 'technical checks only' mode to a 'full data analysis' mode and vice versa. The investigators aim to recruit 30 participants for the pilot study. The study will also run in parallel with its sister pilot trial, LOVE-HF-2.
Through this study, we are testing the capability to get the answers from patients, healthcare systems, and devices, in order to inform future clinical trial design.
Heart Failure is the final common pathway of most forms of cardiovascular disease. In the United Kingdom (UK), it affects around 900 000 people, causes or complicates around 5% of adult emergency hospital admissions and consumes up to 2% of total National Health Service (NHS) expenditure. An important part of discharge planning includes measures such as early follow up in order to prevent readmissions. The hallmark of heart failure is fluid retention and between 2009 and 2016, 43% to 50% of hospital admissions were associated with peripheral oedema. Therefore, early recognition of this and treatment of the congestion may prevent hospital admissions. In clinical trials, management strategies have included patient education, telemedicine and remote monitoring. The main non-invasive method for detecting fluid retention has been the use of weight as a surrogate marker.
The Heartfelt device is an invention that uses a system of cameras in a compact device in order to generate 3 dimensional images of the feet and lower legs. The volumes can then be calculated and thus, changes in amount of peripheral oedema can be estimated. In a clinical trial (NCT02993601) performed by the Heart Failure team at the Royal Brompton Hospital, there was good correlation between measurements made by Heartfelt and a water displacement method. The resolution was as good as 20mls.
By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Images are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. Personal identifiable data (participant name, address, age...) is stored on an encrypted hard drive, along with linkage information (device serial numbers) to associate the participant identifiable data with the data captured in the home. Therefore, data collection is not only secure but entirely passive, which is a major advantage compared with previous non-invasive methods and it is applicable to a very wide range of compliant and non-compliant patients.
Our hypothesis is that the Heartfelt device can directly detect the increase in peripheral oedema associated with heart failure decompensation and that, on average, the number of days with missing data collected by the Heartfelt device will be lower than that of the weighing scales.
Blackpool Victoria Hospital provides acute heart failure service both for in-patients and out-patients, including capacity to administer parenteral furosemide in hospital cardiac day case unit, community or home settings.
Participants with chronic heart failure will be monitored in their home using the Heartfelt device (experimental arm only). Participants in both arms will also receive standard care. "Standard care" means that participants will be encouraged to report symptoms and weigh themselves on a regular basis (as per the recommendation of their doctor or heart failure nurse) reporting them without delay. This will be done in line with current advice given to heart failure patients locally, which is that patients should record their weight in a diary and seek urgent medical attention if their weight goes up by at least 2 to 3 pounds in 24 hours, or 5 pounds or more in one week, or if they notice an increase in leg swelling and/or an increase in breathlessness.
Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per the usual advice given to patients, thus taking part in the study should not change their behaviour. Temporal changes in weight and volume will be compared. Research questionnaires will also be used to estimate the quality of life, mental wellbeing and hope status of participants and collect feedback on the device and study design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with HF ≥18 years.
Exclusion Criteria:
Participant must not be pregnant, and is taking relevant if of *
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
Device: Heartfelt device
Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark. The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless. In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition.
Proportion of participants we can establish number of days alive out of hospital
The proportion of participants for whom we can collect data to establish the number of days alive and out of hospital.
Time frame: 60 days
Proportion of participants we can establish number of days alive and well out of hospital
Proportion of participants for whom we can safely collect data using the study protocol to establish number of days alive out of hospital in which the participant reports feeling well.
Time frame: 60 days
Proportion of participants who complete study questionnaires
Proportion of participants who complete the questionnaires to assess Mental Wellbeing Score, hopelessness, and satisfaction to service provided.
Time frame: 60 days
True alerts - oedema
Proportion of "true alerts" corresponding to "increase in oedema".
Time frame: 60 days
True alerts - diuretics
Proportion of "true alerts" corresponding to "increase in diuretics".
Time frame: 60 days
Proportion of participants we can establish date of emergency hospital admission which is HF related
Proportion of participants for whom we can safely collect data using the study protocol to establish the date of emergency hospital admissions related to HF
Time frame: 60 days
Proportion of participants we can establish date of emergency hospital admission due to any cause
Proportion of participants for whom we can safely collect data using the study protocol to establish the date of emergency hospital admission due to any cause.
Time frame: 60 days
Proportion of participants we can establish date of planned hospital admission which is HF related
Proportion of participants for whom we can safely collect data using the study protocol to establish the date of planned hospital admissions related to HF
Time frame: 60 days
Proportion of participants we can establish date of planned hospital admission due to any cause
Proportion of participants for whom we can safely collect data using the study protocol to establish the date of planned hospital admission due to any cause.
Time frame: 60 days
Proportion of participants we can establish date of death
Proportion of participants in the study for whom the date of death can be established.
Time frame: 60 days
Proportion of participants we can establish cause of death
Proportion of participants in the study for whom the cause of death can be established.
Time frame: 60 days
Proportion of participants we can establish their quality of life
Proportion of participants for whom we can safely collect data using the study protocol to establish participant quality of life.
Time frame: 60 days
Proportion of participants we can establish symptom reporting
Proportion of participants for whom we can safely collect data using the study protocol to establish symptom reporting.
Time frame: 60 days
Proportion of participants we can establish the number of days alive out of hospital in which the participant had significant weight gain
Proportion of participants for whom we can collect data using the study protocol to establish the number of days alive out of hospital in which the participant had a significant increase of weight (including both paper diary records and the provided Bluetooth scales).
Time frame: 60 days
Proportion of participants we can establish the number of days alive out of hospital in which the device did not capture adequate images of the foot to generate a volume
Proportion of participants for whom we can safely collect data using the study protocol to establish the number of days alive out of hospital in which the Heartfelt device did not capture high enough quality images of the participant's foot to generate a volume.
Time frame: 60 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Sep 2021, 6 months.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 6 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heartfelt Technologies